Gene Therapy R&D Market Report 2021-2031
- June 2021 •
- 475 pages •
- Report ID: 6126792 •
- Format: PDF
Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-Oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Hematology, Neurological, Diabetes Mellitus, Other Diseases), by Vector (Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-Viral (Naked DNA, Gene Gun, Electroporation, Lipofection)), by Techniques (Gene Augmentation Therapy, Gene Replacement Therapy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Gene Therapy Companies AND COVID-19 Recovery Scenarios
Gene Therapy R&D Market- Our new study reveals trends, R&D progress, and predicted revenues over the next decade
Facility Expansion Anticipated to Offer Lucrative Growth Prospects
The rise in clinical-stage start-ups has resulted in a shortage of viral vector manufacturing capacity among contract manufacturers, which new gene & cell therapy companies rely on for early-stage development. As these businesses grow to commercial size, they often tend to have complete control over their manufacturing to avoid the complications of outsourcing. As a result, biotech companies started to develop growth strategies, organize internal teams, and/or seek site consultant advice.
Gene Therapies to Offer Promising Results for Patients Over the Next Decade
Gene therapies are among the most complicated medical treatments ever invented. They are producing promising results for patients because they are precisely programmed to replace faulty genes or reprogram and redirect immune cells against cancer. Children who are experiencing vision loss that may lead to blindness will be able to change their course. Cancer patients who have exhausted all other choices may be able to reclaim their lives. Although the possibilities provided by gene therapy seem endless, more work remains to be done to tackle more diseases and increase the number of patients that can be treated and cured using these amazing medicines.
Which Factors Are Driving the Growth of Gene Therapy R&D Market?
. Robust Gene Therapy Pipeline to Boost Growth
. Increasing Investments by Major Players to Augur Market Growth
. Growing Prevalence of Targeted Diseases Treatment
. Technological Advancements to Fuel Market Growth
What are the Opportunities for Gene Therapy R&D Market Players?
. Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
. Facility Expansion Anticipated to Offer Lucrative Growth Prospects
How are prominent players reinforcing their position across the global business?
Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies. See where the expected gains will be. View assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of leading companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and outlook.
Discover how to stay ahead
Our 470+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Gene Therapy R&D Market. See how to exploit the opportunities.
Gene Therapy R&D Market Segmentation
. Rare Diseases: Oncologic, Non-Oncologic
. Cardiovascular Diseases
. Ophthalmic Diseases
. Diabetes Mellitus
. Other Diseases
- Naked DNA
- Gene Gun
. Gene Augmentation Therapy
. Gene Replacement Therapy
. North America
- Rest of Europe
. Asia Pacific
- Rest of Asia Pacific
. Latin America
- Rest of Latin America
. Middle East & Africa
- South Africa
- Rest of Middle East & Africa
COVID-19 Impact Recovery Scenarios
This report includes Baseline Forecasts along with Different Rebound Scenarios to help analyze the global Gene Therapy R&D market-no matter how COVID-19 affects the economy.
Forecasts to 2031 and other analyses reveal the commercial prospects
. In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
. You find original analyses, with business outlooks and developments.
. Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Leading countries and the potential for market growth
Overall world revenue for Gene Therapy R&D market will surpass US$xx in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Gene Therapy R&D Market report helps you
In summary, our 480+ page report provides you with the following knowledge:
. Revenue forecasts to 2031 for Gene Therapy R&D Market, with forecasts for production process, application, product, and material, each forecasted at a global and regional level- discover the industry’s prospects, finding the most lucrative places for investments and revenues
. Revenue forecasts to 2031 for 5 regional and 16 key national markets- See forecasts for the Gene Therapy R&D market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Also forecasted is the market in the US, Canada, Germany, UK, France, Italy, Russia, Japan, China, India, Australia, Brazil, Mexico, GCC, and South Africa among other prominent economies.
. Prospects for established firms and those seeking to enter the market- including company profiles for 16 of the major companies involved in the Gene Therapy R&D Market. Some of the companies profiled in this report are UniQure B. V., Biogen, Bluebird Bio, Spark Therapeutics (Subsidiary of Roche), Bayer, Pfizer, Inc., Applied Genetic, Oxford Biomedica, GenSight Biologics, Takeda Pharmaceuticals, Cellectis, Sangamo Therapeutics, Inc., REGENXBIO Inc., Voyager Therapeutics, Bristol Myers Squibb, Benitec BioPharma, F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Lifesciences, Inc., Sanofi, Transgene, Calimmune, Inc. (CSL Behiring), Astellas Pharma Inc., American Gene Technologies, and Orchard Therapeutics among other prominent players.